Mitchell Ho PhD

Mitchell Ho is a Senior Investigator at the National Cancer Institute, NIH. He received his Ph.D. from the University of Illinois at Urbana-Champaign. Antibody-based therapeutics is a major component in the cancer treatment landscape. However, for many cancers we know little about what tumor antigens can be safely and effectively targeted to discriminate cancers from normal tissues. Dr. Ho studies heparan sulfate proteoglycans including GPC2 and GPC3 as potential co-receptors for Wnt signaling molecules and as new targets for cancer therapy.
His research also demonstrates that ‘single domain antibodies’ can modulate biological processes important for cancer development by binding protein clefts in signaling complexes. By targeting tumor specific shared antigens, his laboratory has developed immunotoxins and CAR T cells for treating liver cancer, childhood cancers and other cancers. Dr. Ho has received many honors including the APAO Scientific Achievement Award. He is the Editor-In-Chief for the international journal ‘Antibody Therapeutics’ and the Chair of the Department of Biochemistry for the FAES Graduate School at the NIH.